Skip to content

Trial · Interventional

CompletedPhase 2Registry data

Glutathione (GSH) In The Treatment of Parkinson's Disease

NCTNCT01177319 (opens ClinicalTrials.gov in a new tab)Other idGSH
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 2
Enrollment
20 participants (actual)
Sponsor
University of South Florida · Other
Design
Randomized · Triple masking
Countries
1 country

United States

Start
Sept 2003
Primary completion
Mar 2007
Completion
Mar 2007
First posted
9 Aug 2010 (estimated)
Last update posted
9 Aug 2010 (estimated)
Conditions
Parkinson's Disease

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
200320042005200620072008
  1. Ph 2

    Glutathione (GSH) In The Treatment of Parkinson's Disease

    NCT01177319

    Sept 2003 to Mar 2007

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This is an investigator initiated pilot study to examine the effects of GSH in PD. The goal of this study is to acquire some basic data regarding side effects and efficacy of this compound to determine if this is a possible treatment option that could be recommended to interested PD patients.

Interventions

  • GlutathioneDrug

Arms0

The registry lists no arms for this trial.

Primary outcomes2

Outcomes the sponsor listed as primary.

  1. Timed walking test

  2. Tapping test

Secondary outcomes(3)

  1. CGI-clinical global assessment by both the physician and the patient

  2. Patient diaries

  3. Parkinson's Disease Questionnaire, a quality of life measurement

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Idiopathic Parkinson's disease (2 of 3 of the cardinal symptoms:tremor, bradykinesia, rigidity) * Mini Mental State Examination \> 24 * Anti-parkinsonian medications stable for one month * Hoehn and Yahr II-IV * Age 18 and above Exclusion Criteria: * Atypical parkinsonism * History of seizure, drug addiction * Use of typical neuroleptics * Previous use of glutathione

PepBank is a research reference. Talk to a doctor before you use any peptide.